Visite du médecin | prix sur demande |
Chirurgie de la hernie discale | $6500 - $8500 |
Ablation par radiofréquence | $6000 |
Chirurgie du cancer du poumon | $10300 - $16400 |
Experience
2019 - 2022 Medipol University
2010 Private Nisa Hospital
2008 - 2010 Kaman State Hospital
Education
2008
Istanbul University Cerrahpaşa Faculty of Medicine, Obstetrics and Gynecology
2002
Istanbul University, Istanbul Faculty of Medicine
Lire la suiteVisite du médecin | prix sur demande |
Thérapie à l'iode radioactif | $5000 - $7000 |
Mastectomie | $5000 - $7500 |
Traitement médicamenteux de la sclérose en plaques | $6000 - $12000 |
Experience
2018
Private Istanbul Medipol Hospital
2018
Medipol University Camlica Hospital
2018
Medipol Camlica Hospital
2013 - 2018
Medipol Mega University Hospital
2011 - 2013
Yuzuncu Yil University Hospital
2010 - 2011
Gulhane Military Medical Academy
2010 - 2013
Yuzuncu Yil University Hospital
2010 - 2011
Gulhane Military Medical Academy
2010 - 2011
Gulhane Military Medical Academy
2010 - 2013
Yuzuncu Yil University Faculty of Medicine
2009
University of Toronto SickKids Hospital
2004 - 2008
Private Van-Etfal Pediatric Diseases
1999 - 2004
Yuzuncu Yil University Hospital
Education
2010
Yuzuncu Yil University, Pediatric Nephrology
2004
Yuzuncu Yil University, Pediatrics
1998
Ege University, Faculty of Medicine
Lire la suite
Visite du médecin | prix sur demande |
Thérapie à l'iode radioactif | $5000 - $7000 |
Mastectomie | $5000 - $7500 |
Traitement médicamenteux de la sclérose en plaques | $6000 - $12000 |
Experience
2017
Private Nisa Hospital
2011 - 2017
Yenibosna Private Ilke Hospital
2007 - 2011
Gaziosmanpaşa Private Bilge Hospital
Education
2005
Bakırköy Dr. Sadi Konuk Training and Research Hospital, Ear, Nose, and Throat Diseases
2005
Bakırköy Dr. Sadi Konuk Training and Research Hospital, Ear, Nose, and Throat Diseases
2000
İstanbul University Faculty of Medicine, Medical Education
2000
İstanbul University Faculty of Medicine, Medical Education
Visite du médecin | prix sur demande |
Thérapie à l'iode radioactif | $5000 - $7000 |
Mastectomie | $5000 - $7500 |
Traitement médicamenteux de la sclérose en plaques | $6000 - $12000 |
Experience
İSTİNYE UNIVERSITY FACULTY OF MEDICINE
Liv Hospital
Liv Hospital Ulus
Acıbadem Bodrum Hospital
Tatvan State Hospital
Tatvan State Hospital
CLEVELAND CLINIC
Dokuz Eylul University Faculty of Medicine
Education
DOKUZ EYLÜL UNIVERSITY FACULTY OF MEDICINE, FACULTY OF MEDICINE/DEPARTMENT OF SURGICAL MEDICAL SCIENCES/DEPARTMENT OF GENERAL SURGERY
Dokuz Eylül University, General Surgery
AKDENİZ UNIVERSITY, FACULTY OF MEDICINE
Title: The impact of sarcopenia on morbidity and long-term survival among patients with peritoneal metastases of colorectal origin treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a 10-year longitudinal analysis of a single-center experience.
Title: Randomized controlled trial of 8 weeks’ vs 12 weeks’ interval between neoadjuvant chemoradiotherapy and surgery for locally advanced rectal cancer.
Title: The effect of fibrin glue in preventing staple-line leak after sleeve gastrectomy: an experimental study in rats.
Title: Treatment of intraoperatively detected peritoneal carcinomatosis of colorectal origin with cytoreductive surgery and intraperitoneal chemotherapy.
Title: Magnetic resonance-based pelvimetry and tumor volumetry can predict surgical difficulty and oncologic outcome in locally advanced mid–low rectal cancer.
Title: Is advanced age a hesitation for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in colorectal cancer?
Title: Outcome of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer: A single-center experience.
Title: Predictive factors for conversion to open surgery in laparoscopic colorectal surgery.
Visite du médecin | prix sur demande |
Thérapie à l'iode radioactif | $5000 - $7000 |
Mastectomie | $5000 - $7500 |
Traitement médicamenteux de la sclérose en plaques | $6000 - $12000 |
Experience
2019 – 2019
Insubria University Faculty of Medicine
2015
2013 – 2015
2010 – 2012
2002 – 2003
Education
2010
1992
Visite du médecin | prix sur demande |
Thérapie à l'iode radioactif | $5000 - $7000 |
Mastectomie | $5000 - $7500 |
Traitement médicamenteux de la sclérose en plaques | $6000 - $12000 |
PROFESSIONAL EXPERIENCE
2011-2012
Erzurum Koprukoyu State Hospital
Department: General Medicine
2012-2017
Istanbul University Cerrahpaşa Medical Faculty
Department: Internal Medicine
06/2017-10/2017
Istanbul Gaziosmanpasa Taksim Training and Research Hospital
Department: Internal Medicine
10/2017-11/2018
Istanbul University Istanbul Medical Faculty
Department: Allergy and Immunology Fellowship
2018/2022
Istanbul University Oncology Institute
Department: Medical Oncology Fellowship
2022-2023
Tekirdag City Hospital
Department: Medical Oncology Specialist
2023-present
Istanbul Medipol University Medipol Bahcelievler Private Hospital
Department: Medical Oncology Assoc. Prof.
EDUCATION
2005-2011
Medical Education
Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey
2012-2017
Internal Medicine
Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey
2017-2018
Allergy-Immunology Fellowship
Istanbul University Istanbul Medical Faculty
Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey
2018-2022
Medical Oncology Fellowship
Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey
2022
ESMO Board Certification in Medical Oncology
10th September 2022 in Paris, France.
2023
Medical Oncology Assoc. Prof.
Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey
INTERNATIONAL CLINICAL TRIALS:
1. Astefania - ROCHE
2. PFİZER
3. RECITE - AMGEN
4. NAVIGATE - BAYER
5. RUBY - Tesaro (PRA)
6. ENGOT-ov43/GOG-3036 - MSD
7. ASTRA ZENECA
8. ROSY-O - ASTRA ZENECA
INTERNATIONAL PUBLICATIONS
I. Published journal articles indexed by SCI, SSCI, and AHCI
Weekly Paclitaxel in Classic Kaposi Sarcoma
Carboplatin Desensitization in Ovarian Carcinoma
High-Dose Chemotherapy for Ewing’s Sarcoma
Multidrug Refractory TFE3(+) Renal Cell Carcinoma
Crizotinib Efficacy in NSCLC with MET Alterations
Clinicopathological Features in ALK Mutant NSCLC
PSMA-Based Tumor Burden in Prostate Cancer
Atezolizumab in Metastatic Urothelial Carcinoma
Pulmonary Sarcomatoid Carcinoma
Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma
Atezolizumab with Chemotherapy in Small Cell Lung Cancer
FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer
Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients
Real-Life Efficacy of Osimertinib in Advanced NSCLC
ALK-Positive Cells Percentage and Alectinib Efficacy
Real-World Data on Alectinib in ALK-Positive NSCLC
Prognostic Factors in Metastatic RCC with T790M Mutation
FLOT Regimen in Metastatic Gastric Cancer
Desensitization Protocol in Lenalidomide Hypersensitivity Reactions
Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity
Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors
Subsequent Treatments in Hormone-Positive Breast Cancer Progression
Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer
Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer
Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer
Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer
Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients
Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients
Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases
FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer
Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer
Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma
Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma
Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)
Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)
Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.
Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49
Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4
Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.
Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY
Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology
Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)
Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)
Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)
Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)
Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye
Thesis:
Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)
International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)
Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination
Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study
Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer
Efficacy of temozolomide in pretreated patients with metastatic sarcoma
Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors
Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma
Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases
Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma
Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study
Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences
Lire la suite
Visite du médecin | prix sur demande |
Thérapie à l'iode radioactif | $5000 - $7000 |
Mastectomie | $5000 - $7500 |
Traitement médicamenteux de la sclérose en plaques | $6000 - $12000 |
Spécialisé dans les troubles neurologiques, le traitement et la réadaptation. Traite l’épilepsie, les troubles du sommeil, les maux de tête, les maladies cérébrovasculaires et les problèmes de mouvement.
Lire la suiteVisite du médecin | prix sur demande |
Chirurgie du cancer du sein | $6000 - $20000 |
Couteau gamma | $4000 - $4500 |
Arthroplastie du genou | $5500 - $12500 |
Visite du médecin | prix sur demande |
Chirurgie de stimulation cérébrale profonde (DBS) | $28000 |
Ultrasons focalisés guidés par résonance magnétique (MRgFUS) | $20000 |
Ablation par ultrasons focalisés de haute intensité (HIFU) | $20000 |
Le médecin est membre de l'Association turque de radiologie, de la Société européenne de radiologie, de l'Association turque de résonance magnétique, de l'Association d'informatique médicale, de la Société turque du cancer du poumon et de la Société européenne d'imagerie oncologique.
Lire la suiteVisite du médecin | prix sur demande |
Chirurgie du cancer du sein | $6000 - $20000 |
Couteau gamma | $4000 - $4500 |
Arthroplastie du genou | $5500 - $12500 |
Visite du médecin | prix sur demande |
Chirurgie du cancer du sein | $6000 - $20000 |
Couteau gamma | $4000 - $4500 |
Arthroplastie du genou | $5500 - $12500 |
Éducation:
Visite du médecin | prix sur demande |
Arthroplastie du genou | $12500 |
Le Dr. est titulaire d'un diplôme de médecine de la faculté de médecine de l'université d'Uludağ, Bursa, Turquie (1983), d'une bourse post-doctorale en thermoradiothérapie de l'université Thomas Jefferson, Philadelphie, Pennsylvanie (1990-1994), et d'une résidence en radio-oncologie du Centre d'oncologie et de médecine nucléaire d'Istanbul, Turquie (1990). Il a également occupé les postes de professeur, président et coordinateur de l'accréditation de la faculté au Collège médical de l'Université Uludağ (1991-2005), professeur et directeur au Centre médical Anadolu (2004-2017), et directeur à l'Hôpital international Ceylan et à l'Hôpital Medicana Bursa (2017-aujourd'hui).
Lire la suiteVisite du médecin | prix sur demande |
Arthroplastie du genou | $12500 |
Dr. X has 10 years of experience in Neurosurgery at Hacettepe University Faculty of Medicine, Diskapi Yildirim Beyazit Training and Research Hospital Neurology Clinic, Yozgat City Hospital, Private Lokman Hekim Akay Hospital, and Emsey Hospital.
Lire la suite